@glueski The initial trial was very small at Mayo--Mayo only was allotted six slots and included people with other blood cancers. I have no idea what happened to the others. It was a worldwide trial. The drug received FDA approval first for Mantle Cell Lymphoma before being approved for other blood cancers including CLL.